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Abstract
The present study demonstrates the effectiveness of
combining medication packaging, verbal and graphical
feedback, and pill count probes on increasing medication
compliance.

Eight chronic adult outpatients were

randomly assigned to one of two conditions:

(a) a

regimen card medication packaging system, and (b) a 7day baggie medication packaging system.

A staggered

group treatment design was used to ascertain whether
either of the two special packaging systems was
effective relative to baseline and reversal conditions
(using the standard medication vial) in increasing
medication compliance behavior among both over-and
undercompliant outpatients.

Results indicated that the

use of the special packaging of medication in
combination with the behavioral techniques of verbal and
graphical feedback aided in improving compliance in 4
out of 8 noncompliant outpatients.
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Improving Medication Compliance With Mentally Disabled
Outpatients
Medication nonc ompliance involves the pati ents'
failure to fulfill the requirements of a prescribed
medical regimen or t o engage in preventive health care
(DiMatteo & DiNicola, 1982).
with psychiatric outpatients.

It is a serious problem
The reluctance of

patients t o take their prescribed medications can lead
to recidivism and rehospitalization (Silberstein &
Blackman, 1966).

A study by Van Patton (1974) estimated

that from 24% to 63% of psychiatric outpatients take
less of their antipsychotic medication than the amount
prescribed.

In the psychiatric inpatient population,

15% to 33% take less than the amount prescribed (Van-Patton, 1974).
There are many variables which influence
noncompliance by psychiatric outpatients to medicat ion
regimens.

Remembering which pill is to be taken is a

serious problem (Diamond, 1983) .

Side effects, such as

nausea, drowsiness, shaking, and even sexual
dysfunctions, discourage outpatients from taking their
medication (Diamond, 1983; Kane, 1983; Michaux, 1961;
Van Patton, 1974).

Patients' own conceptions of their
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illness is another variable (Jamison & Akiskal, 1983;
Marston, 1970).

If the patient is under an assumption

that he or she is not mentally ill, or that he or she is
not ill enough to have to take his or her drugs,
compliance will be lower (Diamond, 1983; Marston, 1970) .
Other variables such as availability of transportation
to obtain medication, money to purchase medication, the
duration of medication treatment (Jamison & Akiskal,
1983), conditions in which going off their medication
makes a patient feel better or, at least, "no worse''
(Gillum & Barsky, 1974), and the lack of understanding
of what their medication does (Diamond, 1983) are all
factors which contribute to noncompliance .
. _ _ Ass_es_s_ment
forms:

_f_or_~tectii1g:_n_()I1_c:ompliance_c~I1

t;ake many

pill counts (Marston, 1970), urinary analysis

(Rickels & Briscoe, 1970), trace measures (Roth, Carson,
& Hsi, 1969), verbal self-reports (Hogan, Awad, &

Eastwood, 1983), and patients' overt behavior patterns
(Stewart & Leighton, 1972).

Various strategies have

been developed to combat the problem of noncompliance,
such as medication education (Cohen & Amdur, 1981),
behavioral self-help techniques (Olarte & Masnik, 1981),
and special packaging (Eshelman & Fitzloff, 1976; Irvin,
1976) •

Diamond (1983) stated that outpatients are more
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likely to comply with visual daily regimens of
medications that are held in plastic containers with
appropriate labels, time frames, and dates of
consumption.
A review of the literature on the measurement of
noncompliance, the effects of medication education,
behavioral self-help techniques to increase compliance,
and the use of special packaging combined with other
treatments on improving medication compliance with the
problem client follows.
Measurement of Noncompliance
There are four principle techniques used to measure
noncompliance: urine analysis, pill counts, therapeutic
interviews, and psychological tests.
Urine Analysis
A urine test can determine whether or not patients
have consumed their medication by examining urine
directly (a) for the drug,

(b) for a derivative of the

drug, or (c) for agents added to the drug for purposes
of detection.

Various studies have demonstrated

successful indications of compliance when implementing a
urine test (Rickels, & Briscoe, 1970; Silberstein &
Blackman, 1966; Wilson & Enoch, 1967) .

Hare and Willcox
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(1967) used urine tests on both male and female
inpatients on two separate psychiatric inpatient wards.
Their results indicated which inpatients were
noncompliant and those who were compliant within both
wards.

Wilson and Enoch (1967) collected 25 urine

specimens from male and female schizophrenic inpatients.
Specimens were collected after each morning dose of
medication.

Urinary analysis indicated the noncompliant

patients on the ward, thus alerting the staff as to
which inpatients were in need of special treatment.
Unfortunately, information obtained from most urine
tests is limited in the accuracy of assessing the degree
of noncompliance

(Rickels & Briscoe, 1970) .

In

- -addition,_the_ use____Qf urinal:"y_ analysis may_ cause _J2<it:_ients
to react to laboratory testing in a negative fashion,
inducing, for example, paranoia in psychiatric
outpatients (Rickels & Briscoe, 1970) .
Pill Cmmts

The pill count is simple and easily administered.
It

involves providing an exact quantity of medication

to a patient and counting the number of remaining doses
at a later date.

This technique provides an advantage

over the urine test analysis in that the presumed amount
consumed may be determined (Boyd, Covington, Stanasek, &
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Cousson, 1974).

However, when using this technique to

measure compliance, the correct number of pills counted
does not necessarily mean the patient has taken his or·
her prescribed amount of medication (Kane, 1983;
Marston, 1970; Rickels & Briscoe, 1970).

Tonguing,

cheeking, or flushing one's medication have been
reported in a variety of undercompliant patients (Boyd
et a1., 1974; Kane, 1983).

(It is important to note,

however, that overcompliant patients do not present this
problem, for it is difficult for them to replace pills
they have already taken.)

A pill count alone is usually

not enough to detect compliance among most patients
(Roth et al., 1969); usually the combination of a pill
count with urine _Qr blood tests is necessary for
accurate detection (Kane, 1983; Roth et al., 1969).

For

example, Roth and Berger (1960) studied ulcer patients
relative to how much antacid they were to take and how
often.

Pill counts were used, followed by a blood and

tracer technique indicating that patients were taking
less than half of the amount prescribed.

It is

advisable to use this technique in conjunction with
others in order to accurately measure medication
compliance.
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Therapeutic Interviews
Various studies have emphasized the importance of
the patient-physician relationship in promoting
medication compliance (Luntz & Austin, 1960; Marston,
1970).

The general purpose of the therapeutic interview

is to find out how patients are feeling as a consequence
of taking their medications and how closely they are
adhering to their prescribed regimen.

Adverse side

effects and a change in symptoms can also be assessed.
Once a physician can relate to his or her patients in an
empathetic, nonauthoritarian manner, assessment of
compliant behavior and education concerning illness and
medications prescribed can take place (Davis, 1969) .

In

addition, during a therapeutic interview, relating in a
manner that does not imply guilt on the part of the
patient and becoming familiar with the patients
themselves can enhance correct interpretation of
responses made in order to detect medication compliance
behavior (Boyd et al., 1974).
The interview has been used either alone or in
combination with other techniques such as pill counts
and tracers (Boyd et al., 1974).

It can allow for a

more in-depth study of subtle i ndications of
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noncompliance.
Self-report may be an inaccurate or inconsistent
measure of medication compliance behavior with the
problem patient.

Bergman and Werner (1963) found 83% of

patients verbally reporting compliant behavior over a
10-day period.

However, objective measures using pill

counts indicated 82% of the patients had stopped taking
all their penicillin by the 9th day of treatment.
The therapeutic interview can serve to help assess
the actions of the patient that relate to a medication
compliance problem and to identify events functionally
related to compliance (Zifferblatt, 1975) .

Overall, the

therapeutic interview is used as a form of assessment in
---"'hich to_ address_i!n_ci_measurEl__ compliant behavior with the
problem patient (Davis, 1969; Marston, 1970; Rickels &
Briscoe, 1970) .
Self-report
Patients' self-report measures have also been used
in medication compliance programs (Epstein & Masek,
1978).

However, they have been found to be unreliable

in assessing how accurately patients comply with their
medication regimens (Epstein & Masek, 1978; Haynes,
Taylor, & Sackett, 1979).

The use of other techniques

with self-report ensures better estimates of compliance
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behavior.
Behavioral Self-Help Techniques
Behavior analysis focuses on the immediate
medication-taking behaviors of the client and the
related antecedents and consequences.

Establishing

compliant behavior requires identification of the target
behavior, performing a functional analysis of that
behavior, and rearranging the environment to facilitate
the occurrence of compliant behavior.

The following

section reviews the effects of reinforcement, selfmonitoring, and self-medication dispensing on medication
compliance.
Reinforcement
Positive reinforcement provides consequences that
increase the probability of compliant behavior.

Some

examples of positive reinforcement include verbal and/or
physical praise for correct responses and selfadministered "treats" contingent upon the client
engaging in the desired behavior of compliance to
medical regimens.

For example, Olarte and Masnik (1981)

conducted coffee groups at an outpatient facility in
order to initiate discussion of medication compliance.
Therapists met with their patients on a weekly basis and
participated for an hour and a half in low-keyed group
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socialization.

Therapists encouraged general

conversation for the first part of the session.

The

second part pertained to medications and prescription
dispensing.

Social reinforcement (meeting with

therapists outside the normal office setting) and
receiving free coffee (as a back-up reinforcer for the
discussion of compliance) combined, led to greater
compliance in keeping weekly scheduled appointments and
more open discussion of medication compliance behavior.
Lowe (1976) studied the effects of reinforcement on
compliant behavior in a female diabetic.

The subject

had three medical responsibilities: (a)urine sampling,
(b) diet maintenance, and (c) foot care.

The

intervention involved posted and instructed memos and
points assigned for completion of each medical
responsibility.

Using horne based treatment, the

subject's mother instructed each self- care behavior at
prescribed times to the subject.

If the subject

complied with the designated self-care behavior within
15 min before or after the time written on her posted
memo or as instructed by her mother, compliance was
scored as "yes."

If the subject did not comply within

the time periods allotted, compliance was scored as
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"no."

Points were given on a weekly basis for

compliance with urine sampling and foot care.

The

subject had to earn a total of 12 points for daily
reinforcers (dietetic sodas and snacks, games, and bike
rides), and a total of 70 points for weekly reinforcers
(movies and special trips) .

Points were displayed on a

daily basis in an area prominent to the subject to
inform her of her level of compliance.

Using points to

exchange for reinforcers, the subject's compliance
behavior increased substantially in all three self-care
areas and maintained through follow-up.
The use of aversive consequences has been successful
in contingency contracting programs for weight loss and

(Haynes et al., 1979).

Haynes (1973) used a contingency

management program with 12 alcoholics who had been sent
to jail.

The program consisted of avoiding a jail term

contingent upon compliance to an Antabuse program for
the same amount of time as the jail sentence.

If they

dropped out of the Antabuse program, their jail terms
were reinstated.

Results indicated that compliance to

the Antabuse program was higher than with conventional
noncontingency programs.
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Self-monitoring
The process of observing and recording one's own
behavior has been found to increase compliance among
many problem patients (Haynes et al., 1979; Sand,
Frieschmann, Fordyce, & Fowler, 1975).

The technique of

self-monitoring has been widely used in weight reduction
programs (Haynes et al ., 1979, p. 184).

Unfortunately,

few studies involving self-monitoring with compliance to
medical regimens have been conducted (Haynes et al.,
1979, p.184).
Sand et al. (1975) studied the effects of selfmonitoring and reinforcement upon noncompliant self-care
behaviors.

The subject was a 27 year old male

paraplegic who relied on the nursing staff to do simple
self-care related tasks that he was capable of doing
himself (tallying the correct number of medications
consumed per day, bathing, and dressing).

The subject

was given a list of self-care behaviors to complete for
each day.

As he completed a behavior, he was to check

it off on the given list and hand it in to one of the
nurses on duty for the day.

During the second week he

was introduced to more self-care behaviors, and if he
completed a specified number , he was awarded a pass horne
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from the hospital.

His compliance rate increased over

the first week and continued to do so for 4 weeks until
discharged.
Self-dispensing Medication
Prompting patients who dispense their own medication
regimens has also been found to be effective in
increasing medication compliance (Azrin & Powell, 1969).
Such programs usually involve reminder tactics in order
to increase the likelihood of compliant behavior.
Azrin and Powell (1969) examined the effects of
self-medicati on dispensing using an operant apparatus
based on response priming and escape reinforcement.

The

apparatus was used with 6 normal adults instructed to
comply with a medical regimen.

The portable apparatus

would sound a tone during a given time

frame~thus

alerting the subjects to switch a lever in order to
terminate the loud tone and eject a tablet providing
escape reinforcement.

This prompting device was

compared to that of a normal wristwatch.

Results were

that 97% of the subjects followed their prescribed
medical regimens using the portable apparatus as opposed
to 16% compliance when using normal wrist watches.

The

authors concluded that the use of response priming can
be effective in increasing compliance with a variety of
patients, especially in the psychiatric population.
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Combining Techniques
Epstein and Masek (1978) used a variety of
behavioral procedures to increase medication compliance.
Seventy-two undergraduate college students participated
in complying to a vitamin C regimen for a 6 week period .
Compliance was assessed by a tracer which discolored
urine; subjects were to report the time of discoloration
to the experimenter.

This report was compared to the

predicted time on the basis of a scheduled sequence of
vitamin C tablets with a chemical tracer.

Subjects were

randomly assigned to 4 groups: self-monitoring, taste,
taste plus self-monitoring, and a n o-treatment control
group.

Half of the students in the above groups

participated in a response cost procedure.

The results

revealed that the self-monitoring, and taste plus selfmonitoring procedures yielded the most appropriate
levels of medication compliance.

The response cost

procedure also produced a marked improvement in
compliance.

The t aste plus self-monitoring procedure

was not significantly different fr om the results of the
response cost procedure a l one on improving medication
compliance.
In summary, the effects of positive reinforcement,
self-monitoring, self-medication dispensing, and the
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combination of these techniques have proven to be very
effective procedures in enhancing medication compliance
behavior.

These techniques enable clients to learn how

to help themselves and not to be dependent upon others
to help them maintain effective and productive lives.
Patient Education
McEvoy (1981} found that 60% of the clients he
studied had a poor understanding of their need for
hospital admission and 56% did not understand their need
for medication.

Lin, Spiga, and Fetsch (1979} found

that only 31% of clients had insight into their illness.
Various studies have found medication education
effective in increasing compliance with a variety of
populations (Cohen & Amdur, 1981; Haynes et al., 1979;
Hecht, 1974}, and physicians, nurses, and community
health workers communicating to clients what their
medications do to help them has been a component in many
compliance programs (Marston, 1970} .
Hecht (1974} studied 47 tuberculosis outpatients,
all of whom (a} had a medication regimen including
isoniazid,

(b) had a negative history of drug addiction

or recent psychiatric illness,

(c) lived at home, and

(d) were referred to a clinic in need of assistance to
comply with a medical regimen.

The objective of the
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study was to teach each patient as much as possible
about the drugs administered, to reinforce what they
already knew about their medication, and to correct any
misinformation.

Three experimental groups received

varying amounts of medication information and individual
instruction by nurses.

Group I was taught about

medications administered in the clinic, Group II was
taught within the clinic and in two horne visits about
the effects of their medication, and Group III was
taught in the hospital before discharge and in the
clinic of their illness and medications prescribed.
Results derived from interviews and pill counts
indicated noncompliance was reduced from 53% in the
control group to 17% of the patients in the group which
received the most intensive instruction.
Cohen and Amdur (1981) examined the effectiveness of
group education to increase compliance in psychiatric
patients.

Six separate group meetings were devised to

help patients understand the role that psychotropic
drugs play on maintaining mental health.

A variety of

problem-solving and task-oriented approaches were used
in the meetings to help patients gain insight into their
own feelings and perceptions about taking medications.
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Each group meeting used a question-and-answer format,
with questions answered by either staff or group
members.

Each group had 6 to 10 patients and met weekly

for 1 hour.

Compliance to medical regimens was measured

by a pre-and post-questionnaire.

Results indicated an

increase in overall understanding of psychotropic
medications and in compliance with prescribed medication
regimens.
Stowell (1983) studied the effectiveness of
education on medication compliance in schizophrenic
outpatients.

Subjects were enrolled in a Day Treatment

Center and followed a workbook as part of weekly
scheduled group meetings.

Education groups consisted of

hourly meetings pertaining to the understanding of

---- - - - - - - -

---- ---------

---

---------

medication compliance, the symptoms of psychosis, and
the understanding of schizophrenia.
groups varied from week to week.

Participants in the

The pre-and post-

education results of 5 participants were analyzed.

The

education group increased all 5 participants'
understanding of medication and increased self-reported
compliance to medication.
Patient education has proven to be a beneficial
component in medication compliance.

Often clients lack

the proper understanding of their medication, its
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purpose, and the importance of complying to their
prescribed regimen.

The above studies indicate that

providing clients with such information is beneficial to
their adherence to and maintenance of their medical
regimens.
Special Packaging Combined With Other Treatments
The effects of special packaging on increasing
medication compliance has been well documented
(Demetral, Gipson, Irvin, Anderson, & Catania, 1978;
Eshelman &, Fitzloff, 1976; Irvin, 1976; Linkewich,
Catalano, & Flack, 1979) .

Special packaging visually

prompts patients when each pill is to be taken and when
a pill has and has not been taken.

Such packages have

been found to be successful in increasing medication
compliance and are preferred by most outpatients in
comparison to the more typical medication vials
(Diamond, 1983) .

The combining of techniques such as

pill counts, tracers, education, and behavioral
techniques with special packaging has demonstrated
significant increases in compliant behavior (Rehder,
McCoy, Blackwell, Whitehead, & Robinson, 1980) .
Eshelman and Fitzloff (1976) studied 100
hypertensive outpatients all taking the drug
chlorthalidone.

Patients were randomly assigned to
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using either a medication vial or a special packaging
technique referred to as PAK.

Sixty-seven patients

received urinary analysis and pill counts to measure
compliance.

Based on the urinary analysis, the patients

receiving the PAK were significantly more compliant than
those receiving the medication vial.

There was no

difference evident in compliance rates as measured by
the pill count.

Results of the pill counts indicated

that patients who received chorthalidone in vials were
61% compliant, . as compared to 63% using the PAK, for an
overall rate of 62%.

Urine analysis revealed 69%

compliance using the vials, 93% using the PAK, and 80%
for an overall rate, respectively.
Rehder et al. (1 980) also studied 100 hypertensive
outpatients.

Patients in this study attended a

hypertensive clinic and were prescribed several
medications a day.
one of four groups:
counseling,

Patients were randomly assigned into
(a) control,

(b) received

(c) received a medication packaged

container, and (d) received the medication package
container plus counseling.

Counseling was done by

physicians, nurses, and pharmacists within a c linic.
Attendance of group meetings and visits to the pharmacy
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were tallied throughout the study.

Results indicated

patients in the medication package container and
medication package plus counseling groups demonstrated
95% or greater compliance, while control group
compliance was 65%, and the counseling-only group
compliance 70%.

Most of the patients within the study

commented that they liked the medication packaging
container better than the medication vials for the
following reasons:

medications were easier to take from

the container, the medication packaged container helped
them to remember to take their medications, and lastly,
the medication package container helped their family
members to remind patients to take their medication.
Young (1983) examined special pill containers as
opposed to vials with 70 hypertensive outpatients.

All

70 outpatients were obtained from an outpatient clinic
and randomly assigned to one of two groups.

Group I

received a special pill container and a posttest; Group
II received regular medication vials and a posttest;
Group III served as the control and received the
posttest only.
period.

Treatment was conducted over a 6 week

The special pill container held medication in

plastic compartments on cards with labels indicating the
time and day each pill was to be taken.

A new
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medication card was distributed each day.

Compliance

was determined by a urine tracer of hydrochlorothiazide,
pulse readings, blood pressure readings, and pill
counts.

All readings took place during each client's

visit to the outpatient clinic.

Results revealed

compliance in the experimental group exceeded 68 . 6%,
while the control group reached 48.6%.
Joyner, Fikrat, and Catania (1983) examined the
effects of special packaging combined with medication
·monitoring, reinforcement, and home interviews with
geriatric patients.

Fourteen patients participated in

an 18-month study.

Treatment consisted of weekly visits

to the patient's home by clinical pharmacists assessing
compliance with medication, counseling on medication,
distributing medication in special packages, and
reinforcing with physical and verbal gestures.

All

patients resided in a home for geriatric patients and
were referred to the program by their physician and/or
family members as having a problem in medication
compliance.

Results demonstrated that compliance to

medical regimens ranged from 82% to 100%.

I t was

determined that special packaging and combined
treatments were able to increase compliance in all
patients, which was maintained throughout follow-up.
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A study by Linkewich, Catalano , and Flack (1979)
examined special packaging and instruction on
outpatients' compliance to medical regimens.

One

hundred and twenty outpatients were prescribed
penicillin tablets, one tablet four times a day for a 10
day period.

All outpatients were randomly assigned to

one of four treatment groups.

Group I received

penicillin in a medication vial with instructions on the
label.

Group II received penicillin in a medication

vial and a calendar prepared with the dates of therapy
and antibiotic administrative times recorded on it.
They were to check off each time they took their daily
dose of medication using this calendar.

In addition

they were given an instruction card describing the
regimen they were to follow , which was read to them by a
pharmacist.

Group III received 40 unit dose packages of

penicillin in the form of special packaged regimen
cards.

They also received a standard label of

instructions on the package and an instruction card.
Group IV received a Wyeth QUID Strip-PAK with standard
labels and instructions.

Outpatients were read

instructions and were given a card, as were patients in
Groups I, II , and III .

Unannounced home visits by a
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pharmacist took place during the 7th and 9th day of
treatment for pill counts.

Results revealed that Groups

II, III , and IV ingested a higher percentage of
penicillin than outpatients in Group I.

Pill counts at

the time of the unannounced interviews indicated that
all outpatients were still taking their medication and
following their prescribed regimen.

Drug taking was

arbitrarily considered as compliant if at the time of
the interview they had taken 90% to 110% of the
prescribed quantity.

Thus, groups receiving special

packaging had higher compliance to the penicillin
regimen than those using the medication vial.
Irvin (1976) studied the use of pill counts and the
Medi-Dose/Medi-Cup system with verbal reinforcement with

-----

6 psychiatric outpatients.

Each patient's regimen was

sealed with information on a card indicating the date,
day of the week, and the time of day to consume
medication .

On the reverse side of the card was the

name of each medication, strength of medication doses,
and prescription number.

Daily unit dose cards were

housed in a file box-like container to keep cards in an
orderly fashion .

Pill counts were made by the

experimenter on several unannounced horne visits during
different times of the day.

The results obtained showed
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an increase in compliance in 4 of the 6 patients.
Effects of the use of verbal reinforcement (such as :
"You're doing fine";
unclear.

"Keep up the good work"), was

With the withdrawal of this variable in the

second treatment phase , it was noted that there was no
deterioration in compliance behavior.
Prompts and reinforcers accompanied by special un it
dose packaging were assessed by Demetral et al. , (1978).
Two separate studies were completed, differentiated by
the presence of an additional treatment phase in the
second study .

The studies consisted of baseline and

reversals, using vials, special packaging, and verbal
reinforcement (such as positive praise: "Keep it up
you ' re doing great!") and a final phase using special
packaging , alone , in Study Number Two.

The first study

consisted of 8 subjects, and the second study used 6
subjects.

All patients were obtained by referral from

psychiatrists in a county/state inpatient facility .
Special unit dose packages of medication were displayed
on cards, enabling patients to visually ascertain if
they had taken daily doses of medication.

The results

of both studies yielded 81% to 100% from baseline to
treatment phases in all 14 patients ' compliant behavior
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using special packaging, verbal reinforcement, and
special packaging alone.
The present study attempted to demonstrate the
effectiveness of combining some of the treatments and
assessment techniques reviewed above, using special
packaging techniques, and pill probe counts, in addition
to verbal and graphical feedback.

It was hypothesized

that special packaging of medication would yield more
appropriate levels of compliance in comparison to the
standard medication vial.

In particular, the special

packaging technique of a regimen card was hypothesized
to yield more appropriate levels of compliance in
comparison to a 7-day plastic baggie special packaging
technique.

Further, patients who take too much of their

prescribed medications served as some of the
participants.

Primary attention in past studies has

focused on the undercompliant patient.

However,

patients who abuse or take too much of their prescribed
regimen, are also in need of assistance.

Abusive

patients also provide a better measurement of compliance
when using pill counts, since the patient cannot distort
the pill count to appear to be compliant through
disposing of medications by flushing them down the
toilet or cheeking, hiding pills between the gum and
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cheek, etc .

This study investigated the utility of

combining various techniques with both abusive and
undercompliant chronic psychiatric outpatients in order
to establish more appropriate levels of medication
compliance
Method
Participants
The participants consisted of 8 chronic mentally ill
outpatients, ranging from 29 to 60 years of age.

All

clients were obtained from either the University of the
Pacific's Community Re-entry Project Medication
Compliance Program, San Joaquin County Mental Health
Center's Day Treatment Program, or from the head
Clinical Pharmacist at San Joaquin County's Mental
Health Center.

All clients were referred to the present

study due to their past history of suspected
noncompliance either in the form of abusive or
undercompliaot behavior on a daily or weekly basis
(including taking all their medication at one time,
taking more or less than prescribed at one time or
another, and/or selling their medication).
Client 1 was a 60-year-old, divorced, Caucasian
female, who carried the diagnosis of paranoid
schizophrenia.

She had a reported long history of abuse
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with her antiparkinson medication.
year-old, Caucasian male .

Client 2 was a 37-

He was divorced and carried

the diagnosis of paranoid schizophrenia.

In addition he

had a reported long history of drug abuse and
overmedicating with his medication regimen.

He had been

known to buy his antiparkinson medication on the street
when he ran out of his weekly supply .

Client 3 was a

42-year-old single , Black army veteran.

He he l d the

diagnosis of schizoaffective disorder and was reported
to be both over- and undercompliant with different
components of his medication regimen.
35-year-old single , Caucasian male.

Client 4 was a
He was reported to

often forget to take his medications and was therefore
undercompliant; he carried the diagnosis of manic
depressive illness with paranoid tendencies.

Client 5

was a 46-year-old, divorced, Caucasian male.

He had a

reported history of undercompliance to his medication
regimen and was diagnosed as a chronic schizophrenic.
Client 6 was a 43-year-old, Caucasian, recently divorced
male.

In the past he had had a reported history of

sporadic undercompliance, and he was diagnosed as a
paranoid schizophrenic , chronic, with acute
exacerbations.

Client 7 was a 36-year-old, divorced,
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Caucasian female.

She was divorced , with a reported

history of undercompliance and abuse with several of the
medications in her medical regimen.

She was diagnosed

as having an adjustment disorder , mixed, with
depression.
male.

Client 8 was a 29-year-old, single , Mexican

He had a reported long history of drug and

alcohol abuse.

He was both over-and undercompliant with

components of his medication regimen and carried the
diagnosis of chronic schizophrenia, undifferentiated.
Data pertaining to demographic information and each
client 's medication regimen were obtained at the end of
the study and can be found in Table 1.

Clients'

regimens were changed periodically throughout the study
by their physicians, the regimens listed in Table 1 are
those that the clients were adhering to at the end of
the study.
Materials
Participant recruitment.

A formal letter was sent

to the Director of Outpatient Services , the Director of
Community Treatment Services , the Director of Day
Treatment Services , and Clinical Head Pharmacist, all at
San Joaquin County ' s Mental Health Center (Appendix A).
This letter described the study, the clients needed for
participation in the study, and the dates the study
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would begin and end.
This was followed by several phone calls to set up
personal meetings with the Directors and the Head
Pharmacist.

Each meeting entailed a complete

description of the proposed study, including a
description of the objectives of the study, the
hypothesis, a demonstration of the medication packaging
systems that were used, the specific time and date that
the study would begin and end, and the dates clients
would be on baseline and treatment packages.
Table 1: Demographic Medication Data

CLIENT

MEDICATION

STRENGTH

REGIMEN

1

Anane

5mg

1 tablet, 2 times daily

2

Anane

5mg

1 tablet, 3 times daily

Tofranil

25mg

1 tablet at bedtime

Cogentin

2mg

1 tablet, 2 times daily

Lithium

300 mg

2 tablets, 2 times daily

Anane

100 mg

1 tablet at bedtime

Lithium

300 mg

1 tablet, 3 times daily

Mellaril

100 mg

1 tablet, at bedtime

3

4

31

5

Prolix in

lOmg

3 tablets at bedtime

6

Loxitane

50mg

2 tablets at bedtime

Artane

2mg

1 tablet, 2 times daily

Lithium

300mg

1 tablet, 2 times daily

Navane

5mg

1 tablet, 3 times daily;

7

and 2 at bedtime
Lithium

50mg

1 tablet 2 times daily;
and 4 at bedtime

8

Loxitane

25mg

3 tablets at bedtime

Artane

5mg

1 tablet, 2 times day

Table 1: Demographic Data
Client #1

Client#2

Client #3

Client#4

Sex

F

M

M

M

Age

60

37

42

35

Race

Caucasian

Caucasian

Black

Caucasian

Marital

Divorced

Divorced

Single

Single

Status

32

20

13

20

16

0

2

5

0

Diagnosis on

Paranoid

Paranoid

Schizoid-

Manic

Axis I

Schizophrenia

Schizophrenia

affective

Depressive

Undercompliant

No

No

Yes

Yes

Abusive

Yes

Yes

Yes

No

Genetic

Yes

Yes

Yes

No

Environmental

No

No

No

Yes

History of

No

Yes

No

No

Years in
Mental Health

Hospital
admissions
in the last

two years

Drug Abuse
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Table 1: Demographic Data Continued
Client #5

Client #6

Client #7

Client#8

Sex

M

M

F

M

Age

46

43

36

29

Race

Caucasian

Caucasian

Caucasian

Mexican

Marital

Divorced

Divorced

Divorced

Single

23

20

6

9

1

2

5

0

Status

Years in
Mental Health

Hospital
admissions

in the last
two years

Diagnosis on

Chronic

Paranoid

Adjustment

Schizophrenia

Axis I

Schizophrenia

Schizophrenia

Disorder

Undifferentiated

Mixed
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Undercompliant

Yes

Yes

Yes

Yes

Abusive

No

No

Yes

Yes

Genetic

Yes

Yes

No

No

Environmental

No

No

Yes

Yes

History of

No

No

No

Yes

Abuse

Following these steps, I sent a letter to all of the
outpatient doctors, social workers, and case managers
signed by the Directors of Outpatient Services and of
Community Treatment Services, to inform them of the
study and to ask if they had any clients who would
benefit from such a program (Appendix A) .

All referrals

were made to the Head Clinical Pharmacist, who drew up a
list of possible clients to participate.
Referral card/consent form.

Each client's social

worker, case manager, or outpatient doctor was required
to fill out a referral card/consent form indicating the
client's name, address, phone number, diagnosis,
medication(s), and degree of noncompliance in the form
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of antecdotal reports written at the bottom of the card
(Appendix B).

I obtained the form and kept it on file .

An additional referral card/consent form was obtained at
the end of the study from each client ' s doctor during an
informative meeting describing the client's progress
while in the medication compliance study .

The

additional referral card/consent form was collected to
refer the client's to either (a) the Medication
Compliance Program at Community Re-entry Project;

(b) 1-

day medication compliance at the Mental Health Center;
or (c) weekly medication compliance at the Mental Health
Center, utilizing any of the packaging systems used in
the present study after it had ended.

This referral

card/consent form was returned to the Mental Health
Center's pharmacy for their records.
Reguest-for-doctor ' s-assistance form.

The physician

of each client referred to the present study was given a
request for assistance and permission form to sign for
their client's admittance into the medication compliance
study (Appendix C) .

This form described the packaging

system of the regimen card and 7-day baggie system and
the purpose of special packaging techniques .
Consent for participation in the medication
compliance study.

Each client who participated in the
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study was required to read, sign, and date a c onsent
form indicating that they agreed to participate in the
medication compliance study (Appendix D) .

In addition ,

this form stated that clients al l owed me access to their
personal outpatient files, to have their prescripti ons
filled at the Mental Health Center ' s Pharmacy, and t o
have their medication packaged i n the regimen c a rd, 7da y baggie system, and the medication vial .

This f orm

also indicated that the packaging systems used were not
child resistant and that all packages shoul d be kept out
of children ' s reach.
Special Packaging Techniques
The medication vial .

Al l 8 clients received a

medication vial with prescribed medication for a 7 day
interval .

Each vial had a label with written

instructions indicating the type(s) of medication ,
dosage(s) prescribed, and the time intervals in which
they were to be taken (Figure 1).

Each c l ient's

prescription was filled by one of the c l inical
pharmacists at the San Joaquin Mental Health Center ' s
pharmacy .

Each client's medication regimen was

specially packaged by a University of the Pacific
pharmacy intern apprenticing at the Mental Heal th Center
Pharmacy, and then it was labeled appropriately and
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picked up by me to be hand delivered to each client on a
weekly basis.
The regimen card package.

The regimen card was 17.8

x 12.7 em of thin cardboard with written instructions
indicating the days of the week and time intervals in
which medication was to be taken (Figure 2).

Daily

doses of medication(s) were held in small see-through
plastic bubbles on the card to clearly indicate if the
client had or had not taken his or her correct dosage of
medication.

The medication was removed from the bubbles

by depressing the see-through bubble with an index
finger.

Each client's medication was packaged and

obtained by the same personnel as those who did the
medication vial.
The 7-day baggie package.

Clients using the 7-day

baggie package received seven separate clear zip-lock
plastic baggies.

Each baggie contained the client's

prescribed medication(s) regimen for a particular day,
including the specific intervals in which they were to
be taken (Figure 3) .

Instructions indicating the time

intervals for drug consumption were written on each
baggie.

Medication in each baggie was individually

stored in smaller zip-lock bags with the appropriate
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labels, instructions, and intervals in which
medication(s) were to be consumed.

Each client's seven

baggies were delivered in a larger bag, the larger bag
thereby containing a weekly regimen of medication.

Each

client ' s medication was obtained and packaged by the
same personnel who did the medication vial and the
regimen card packaging systems.
Feedback form .

At the end of each week of

treatment, I presented the clients a line graph of the
data obtained from (a) collecting the medication package
used the week before and from counting the number of
pills remaining compared to the number that should be
there according to the client's prescribed regimen, and
from (b) the one weekly unannounced pill probe count by
myself.

The line graph was used to show clients their

weekly l evel of compliance throughout the study (Figure
4) •

Verbal feedback.

At the end of each week during the

col lect ion of the "used packaging" systems from the week
before and the dispensing of the new week's medications ,
clients received feedback on their compliance behavior.
At this time, line graph data of each client's progress
throughout treatment were shown to al l clients.
were reinforced by positive feedback statements

Clients
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including:
"Look Joe, out of an entire week's supply of
medication, you only missed two pills!

That 's very

good; next time let's try to get this number down to one
or zero pills missing.

I can see both from this line

graph and when I come to visit you that you are doing
well and trying hard.

Keep up this good work, I'm proud

of you!"

Figure

1.

The medication vial containing a week's

prescribed regimen of medication, with instructions
indicating the name of medication, dosage(s), and time
intervals it was to be consumed.
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The feedba ck form, used to inform

clients of their weekly level of compliance, visually
through a line graph presented at the end of each week.
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Design
All 8 clients were randomly assigned to groups with
an equal number of clients in each group (Table 2).
Group I received the regimen card package and Group II
received the 7-day baggie package following the initial
baseline phase.

The initiation of treatment was

staggered so that Group I received treatment after 1
week of baseline, while Group II received treatment
after 2 weeks of baseline.
a period of 2 weeks.

All treatment phases lasted

The first treatment phase for each

client was referred to as Treatment A, the second phase
as Treatment B, and return to use of the vials was
referred to as

reversal~

Following the first treatment

phase, lasting 2 weeks, clients were returned to using
the baseline package of the medication vial for 2 weeks,
and then placed on the treatment package they had not
yet used for 2 weeks, with a final return to the
medication vials for another 2 weeks.

During the last 2

weeks of treatment, clients were to pick, out of the two
medication packaging systems and the medication vial,
the one they wanted to use for the last phase of the
study, referred to as Treatment C (or Reversal 3 if they
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selected the vial) .

The performances of both Groups I

and II were compare d to their own performance using the
medication vial throughout the study.

Both groups were

compared to evaluate which treatment package was more
effective in producing appropriate medicati on compliant
behavior.
Table 2: Design Of The Study

Group 1: Baseline and intervention sequence; two pill probes conducted each week
throughout the study.

Phase

Packaging Technique

Length of Phase

Actual Weeks

Baseline

vial

2 weeks

1-2

Baseline/

vial

11 weeks

3-throughout

Treatment A

cards

2 weeks

4-5

Reversal 1

vial

2 weeks

6-7

Treatment B

baggies

2 weeks

8-9

Introduction
to feedback
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Reversal 2

vial

2 weeks

10-11

Reversal 3
or
Treatment C

vial

2 weeks

12-13

cards or baggies

2 weeks

12-13

Group 2: Baseline and intervention sequence; two pill probes conducted each week
throughout the study.

Phase

Packaging System

Length of Phase

Actual Weeks

Baseline

vial

3 weeks

1-3

14 weeks-

4-throughout

~aseline/

vial

-

Introduction
to feedback

Treatment A

baggies

2 weeks

5-6

Reversal 1

vial

2 weeks

7-8

Treatment B

cards

2 weeks

9-10
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Reversal2

vial

Reversal 3/vial
or
Treatment C cards or baggies

2 weeks

11-12

2 weeks

13-14

2 weeks

13-14

Definition of compliance.

Compliance in this study

was defined in terms of how closely clie nts followed
their prescribed medication regimens.

If it was found

that the client was behind or ahead of his or her weekly
medication regimen by one or more pills at an
unannounced pill probe on any of the prescribed
medication(s), the client was considered noncompliant .
Each client followed his or her prescribed medication
regimen in dosage(s) and within the correct time
frame(s)

in order to be cons idered compliant.

A mean

from 80% to 100% was designated as the set point for
appropriate compliant behavior in relation to each
c l ient' s medication regimen.
Procedure
Baseline .

Group I received 1 week of baseline and

Group II received a 2 - week baseline period.

At this

time clients were instructed to comply as they normally
would if not in the program, using the medication vial .
Each client was told:
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" I will be handling your medication under the
medication compliance study in which you have consented
to participate .

I will pick up your wee kly medication

regimen and deliver it to you r home every Friday , at
which time I will collect the vial used the previous
week.

In addition I will make one other visit to your

home each week to see how you are doing on your
medication, to see if you have any personal requests
regarding your medication, and to count the number of
pills remaining in your vial and compare that to what
your prescription(s) have indicated t hat you should be
taking."
Following these instructions, clients were then
placed on the medication vial for 2 weeks .

One random

unannounced pill probe was conducted per week in which I
counted the number of pills taken and compared that
number with the prescribed regimen .

I made unannounced

pill probes checks during the time frames specified by
each client as those in which they were most likely to
be at home.

The specific times and day for each home

visit differed each week according to the client ' s
schedule, about which they informed me upon delivery of
medication during the preceding week.

Several possible

days and the time frames per day of availability were
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determined each week for pill probes; the day and time
of day selected was randomly picked for each week of the
study.

A schedule was kept indicating the sequence of

days and time frames I visited each client for the
unannounced pill probes .

If the same day or time frame

matching the preceding week was picked, I made another
random selection of a time to make the unannounced
visit.

If by chance the client was not at home, another

unannounced home visit was made later on that day or the
day after.

As many trips as necessary were made to the

client ' s home to obtain the information needed for the
pill probe checks.
Treatment.

Following baseline, clients in Group I

continued on the medication vial for an additional 2week period.

At this time I provided them with both

verbal and graphical feedback at the end of each week,
upon the collection of the old medication packaging
system.

Verbal and graphical feedback was continued

throughout treatment .

In addition, I presented Group II

verbal and graphical feedback following baseline.
At the staggered implementation of treatment,
clients were placed on the packaging system in
accordance with the group to which they were randomly
assigned to during baseline .

Group I received the
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regimen card package for a 2-week period.

I gave each

client a complete demonstration on how this package
worked.

I informed clients that I would deliver their

weekly medication regimen, collect the medication
package from the week before, regardless of the number
of pills missing or remaining, and that I would make one
weekly unannounced pill probe check on their medication.
These instructions were the same for those in Group I as
in baseline.

I presented verbal feedback to each client

regarding appropriate compliant behavior, and data was
presented visually on a line graph to show the changes
in compliant behavior compared to baseline data.

Verbal

and graphical feedback data were followed by the same
instructions as those given during baseline.

If the

client was behind or ahead of his or her weekly
medication regimen by one or more pills, I gave
corrective feedback.
statements as:

Corrective feedback included such

"Joe, out of a week's regimen of

medication you have missed eight of your pills.
explain this to me and why?

Can you

Next time let's try to

decrease this number by at least two.

Your medication

compliance behavior is important.

It will help to keep

you well and out of the hospital.

Try a little harder
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to remember when and when not to take your pills for the
next week."
Following the 2 week period on the regimen card ,
clients returned to the medication vial for an
additional 2 weeks.

Afterwards clients were placed on

the 7-day baggie system for 2 weeks.

A complete

demonstration with instructions on how to use this
package was offered by me.

Following this 2-week phase,

clients returned to the medication vial for an
additional 2 weeks.

Pill probe counts, line graphs, and

verbal feedback given initially on the regimen card
packaging system occurred throughout subsequent reversal
and treatment phases.
I asked each client the best times during the day to
find him or her at home to receive medication(s).

In

addition, each c lient ' s phone number was obtained to
check the times each week that he or she was home.
Group II received the 7-day baggie package for a 2week period.
worked.

I showed each client how this package

Clients were required to comply with one weekly

unannounced medication pill probe check, provide me with
the remaining package from the week before, and to
comply as best they could throughout the treatment
phase .

Following a 2 week period on the 7-day baggie
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system, clients returned to the medication vial for an
additional 2 weeks.

After this time period, clients

received the regimen card packaging system for 2 weeks.
I gave a complete demonstration with instructions on how
the regimen card packaging system worked.

Following

this 2-week period on the regimen card package, clients
returned to the medication vial for an additional 2
weeks.

The instructions, graphical data, and verbal

feedback given to the clients in Group I were the same
for the people in Group II.

At the end o f treatment,

clients in both groups were shown graphically, their
level of medication compliance for the ent ire study .

I

pointed out which medication(s) were either missed or
abused and pointed out their mean level of medication
compliance in such statements as: "You had some
difficu lt y at the beginning of the study, but now you
have obtained a mean of
behavior.

medication compl iance

This is a marked improvement.

Congratulations!"

Or , if the client had demonstrated

progressively poorer medication compliance behavior,
structured feedback such as:
"Joe, after reviewing your data, it does not appear
that you have increased your medication compliance
behavior and you have actually gotten worse.

You should

consider the Community Re-entry Medication Compliance
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Program on a long term basis to help you in taking your
medications."
The clients were encouraged to comment on the
special packaging systems used as to their preference
and asked if they felt the combined techniques of
special packaging, pill probe counts, and weekly verbal
and graphical feedback aided in compliance behavior.

I

then told told them they had the option to either
continue in a modified program at Community Re-entry
Project or return to their regular method of medication
dispensing.

This decision was ultimately made by the

client and his or her case worker or physician.
Results
The mean percentages of each client's medication
compliance behavior were taken throughout the study.

To

obtain a figure representing the percentage of pills
that were consumed by each client at the time of the two
weekly pill probes, the number of pills taken was
counted and that number was divided by the actual number
prescribed; this number was multiplied by 100.

Appendix

E presents the raw data for each client calculated
throughout the study for Groups I and II.
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Figure 5

Client One was

compliant with Elavil .

abusive with Artane, and

The medication of Elavil was

added to her regimen during Reversal 3 .

Axis x denotes

the percentage of compliance ; axis y designates the
number of pill probe days.
Cl ient One .

This client was referred to the study

by her case worker due to her reported severe long- term
medication compliance behavior of overmedicating with
her antiparkinson medication of Artane (Figure 5) .
Dur ing the 3 weeks of basel ine (Weeks 1-3), the client
obtained a mean of 104.4% with a standard deviation of
16 . 4% while on Artane (which was not representative of
her reported past abusive behavior patterns as indicated
b y her pharmacist and psychiatrist) .

During Weeks 2-3 ,

the presentation of verbal and graphical feedback was
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introduced.

The client's behavior continued to

fluctuate both above and below satisfactory levels of
compliance upo n the initiat i on of feedback.

Overall

levels of compliance during treatment phases was 124.9%,
with a standard deviation of 4.4 % for both medications.
She obtained an average of 119%, standard deviation of
16.5 %, while on Artane, and 99.8 %, standard deviation of
13%, on Elavil, after its introduction during the last
phase of treatment.
During the first phase of the study , indicated as
Treatment A, the client was instructed to obtain her
medication from the special packaging technique of the
regimen card.

The implementation of this technique

yielded a mean of 121.8%, standard deviation of 13 . 3%,
indicating a slight elevation in overmedicating, in
comparison to baseline measures.

Treatment B, using the

7-da y baggie packaging system, indicated a slight
improvement in compliance to a mean level of 128 %, with
a standard deviation of 16.2%.

This figure was 6.2

percentage points higher than when using the regimen
card packaging system, and 40.5 percentage points
improvement in compliance when compared to the reversa l
with the vial.
Overall reversal phases indi cated mean compliance to
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Artane of 138%, standard deviation of 33.0%.

Upon the

initial implementation of Elavil, during the final
reversal phase, her mean compliance was at 99.8%, with a
standard deviation of 13.5%.

Following the introduction

of the regimen card during Treatment A, a reversal to
the vial demonstrated a marked increase in
overmedicating, with a mean of 168.5%, standard
deviation of 36.4%.

This was close to reports of her

past abusive behavior.

The second reversal to the vial

revealed a mean of 142.4%, standard deviation of 42.5%,
in compliant behavior.

For the final phase of the study

the client indicated that her choice of packaging system
was to be the vial for the remaining 2 weeks.

At th i s

point the

medLc~tLon

of Elavil was added to her medical

regimen.

Mean compliance to the Elavil regimen was at

99.8%, standard deviation 13.5%.

Her mean Artane level

was 106%, standard deviation 14.5%, during this last
phase.
Results obtained for Client One indicated that both
special packaging techniques had a positive effect on
her overmedicating behavior with Artane in comparison to
reversal Phases 1 and 2, but not in comparison to
baseline.

Slightly more appropriate levels of

compliance were obtained while using the regimen card as
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opposed to the 7-day baggie packaging system.

During

the final weeks of the study she chose to cont inue using
the vial as opposed to the special packaging systems.
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Figure 6

Client Two was abusive with his Artane,

and compliant with his Cogentin and Imipramine
medications.

The medications of Tofranil and Cogentin

were added to his regimen during Reversal 3 .

Axis x

denotes the percentage of compliance; axis y designates
the number of pill probe days .
Client Two.

The client was referred to the study by

Community Re-entry Project due to his reported long term
severe abusive behavior with his antiparkinson
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medication of Artane (Figure 6).

Baseline compliance to

Artane was 173%, standard deviation of 85%, a figure
considerably less than his past abusive overmedication
behavior as described by his board and care home
operat or.

Verbal and graphical feedback was introduced

begi nning the 2nd week of baseline and continued
throughout the study.

Upon the initiation of verbal and

graphical feedback, his compliance level went to 210%.
Overall levels of compliant behavior during
treatment phases for the entire study revealed a mean of
178%, with a standard deviation of 21.5%, while on
Artane.

Treatment A, using the regimen card packaging

system produced 193.5% mean compliance, with a standard
deviation of 45.6%, for Artane consumption, slightly
better than verbal and graphical feedback alone.

During

the initiation of Treatment B, using the 7-day baggie
packaging system, the client exhibiting 163% compliance,
standard deviation of 31.2%.
Reversal phases yielded a comprehensive mean level
of compliance of 230.5%, standard deviation of 34%.
Mean overall Tofranil compliance for the study was 133%,
standard deviation 0%.

Cogentin was added to the

regimen in place of Artane during the final weeks of the
study, which yielded a mean of 82%, standard deviation
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of 35%.

Reversal to the vial following the

implementation of Treatment A using the regimen card
packaging system, produced a dramatic degeneration in
behavior of 270% mean compliance with a standard
deviation of 92.4%, indicating that prior treatment with
the regimen card had some effect on the client's
compliance behavior.

This gross increase in

overmedication suggests the effectiveness of the regimen
card packaging system in yielding more appropriate
levels of consumption.

Following a reversal to the vial

after using the 7-day baggie packaging system as
Treatment B, the client's behavior again slightly
deteriorated to a mean of 211.5%, standard deviation of
24.8%, suggesting that prior treatment with the 7-day
baggie packaging system had some effect on his behavior.
For the final phase of the study, the client chose
to maintain use of the vial.

His Artane compliance

stayed at a mean of 210%, standard deviation of 0%, for
the 1st week of this phase.

Following a meeting with

the client's psychiatrist to inform him of his patient's
behavior during the study, his regimen was changed to
Tofranil and Cogentin to aid him in appropriate
medication compliant behavior.

Cogentin was added in

place of Artane because when it is abused, it produces
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little or no sensation of feeling "high" as does Artane.
His compliance was somewhat better with a mean level in
compliance of 133%, standard deviation 0%, while on
Tofranil.

The implementation of Cogentin yielded the

best overall level of compliance with a mean of 82%,
standard deviation 35%.

Results indicate that the

special treatment packages aided in improving the
client's medication compliance in comparison to reversal
phases when the vial was used.
Client Two demonstrated more appropriate levels of
compliance to Artane during Treatment B while using the
special packaging system of the 7-day baggie in
comparison to reversal Phases 1 and 2 and the
--implementation of- Treatment A using the
packaging system.

regi~~ard

However, prior initiation of the

regimen card may have contributed in cueing the client
to reduce his intake of Artane.

The client's best leve l

of compliance occurred during the final reversal, while
using the vial.

This reduction in medication abuse

might be attributed to a change in his medical regimen
following a meeting with his psychiatrist.

At this

point the client was taken off Artane and placed on
Cogentin and Imipramine.

Cogentin was substituted for
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Artane, due its ability to reduce parkinsonian-like
symptoms without the "high" that Artane often produces.
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Client Three was abusive with both Artane

and Lithium medications.

The medication of Lithium was

added to his regimen during Treatment A.

Axis x denotes

the percentage of compliance; axis y designates the
number of pill probe days.
Client Three.

The client was referred to the study

by The University of the Pacific's Community Re -entery
Project, due to his reported moderate long-term abusive
behavior with his antiparkinson medication, Artane and
his antipsychotic medication Lithium (Figure 7) .
baseline (Weeks 1-3), he exhibited a mean of 115%

During
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compliance to Artane, standard deviation of 29%,
slightly better than his estimated level of compliance.
During Weeks 2-3 he was presented with both graphical
and verbal feedback, which continued throughout the
remainder of the study.

The initiation of verbal and

graphical feedback appeared to improve his medication
compliance behavior.
The overall mean level of compliant behavior for
treatment phases for both medications was 103.%,
standard deviation 12%.

Comprehensive mean for all

treatment phases while on Artane was
deviation 10%.

104.8%, standard

On Lithium mean compliance was 96.7%,

standard deviation 21%, for all treatment phases.
Compliance to Artane improved subsequently during
Treatment A on the regimen card packaging system to
100%, 0% standard deviation in comparison to baseline
measures.

At this time Lithium was added to the

client's regimen, resulting in a mean compliance of
88.6%, standard deviation 19.6%.

Treatment B, using the

7-day baggie packaging system, produced an improvement
in mean compliance to 101.5%, standard deviation of
2.8%, for both Artane and Lithium.

Compliance for

Artane during Treatment B was better, in comparison to
the first reversal to the vial, by 40 points at 101.2%,
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standard deviation 2 .5%.

Lithium compliance during this

phase improved to 101.7%, standard deviation 3.5%.

For

the final 2 weeks of the study the client chose to use
the regimen card for Treatment C.

Artane compliance

during this final phase of treatment improved to a mean
of 113% , standard deviation 15.6%; Lithium mean
compliance was 110%, standard deviation 12.9%.

These

results suggest that the packaging system aided in
appropriate medication compliant behavior for this
individual client .
Mean compliance for overall reversal phases for the
entire study was 109%, standard deviation 46.9%, for
both medications.

The clients' mean compliant behavior

was at 164%, standard deviation 58.9% for al l reversal
phases on Artane .

Reversals on Lithium demonstrated

better mean compliance at 97%, standard deviation 21%.
Reversal to the vial, following Treatment A using
the regimen card packaging system, suggested that the
regimen card had a positive effect on his behavior.

He

regressed in mean compliance with Artane to 141%,
standard deviation 37%; Lithium mean compliance dropped
below satisfactory levels to 76.8%, standard deviation
31% .

Following a return to the vial, after the
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implementation of the 7-day baggie packaging system as
Treatment B, Artane mean compliance deteriorated to
187.5%, standard deviation 72%.

Lithium mean compliance

remained at an appropriate level of 102.75%, standard
deviation 46.6%.

In summary, Client Three maintained

almost perfect levels o f compliance for Artane while
using both special packaging techniques in comparison to
both baseline measures and reversal Phases 1 and 2.
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Client Four was undercompliant with the

medications of Mellaril and Lithium.

Axis x denotes the

percentage of compliance; axis y designates the number
of pill probe days.
Client Four.

The client was referred to the study
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by his Day Treatment Team Leader due to his reported
long term

moderate undercompliant behavior (Figure 8) .

However, he terminated from the study before all
treatment and reversal phases were implemented.

For

financial reasons, the client was moved into a board and
care home, where medications were dispensed by the home
operator .
During baseline he achieved a combined mean for both
medications of 68.5% compliance, with a standard
deviation of 39.6%.

Lithium compliance during baseline

was at 50.8%, standard deviation 44.5%.

Compliance with

Mellaril during baseline was within appropriate levels
for compliance at 86%, standard deviation 26.8%.

These

figures were not representative of his reported past
undercompliant behavior as indicated by his Day
Treatment Team Leader, who recalled it to be much worse.
During Weeks 2-3, the presentation of verbal and
graphical feedback was introduced.

The initiation of

feedback had some effect in reducing his undercompliant
behavior, with Lithium as indicated, following Week 1 of
baseline.

However, the initiation of feedback yielded a

severe decline in compliance with Mellaril.
Treatment A, using the regimen card packaging
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system, yielded a mean of 100%, with a standard
deviation of 0%, for both Lithium and Mellaril.
Following reversal to the vial his combined compliance
behavior dropped 5 points to a mean of 95%, with a
standard deviation of 11.8%.

Mean compliance with

Lithium during this reversal regressed 10 points to 90%,
standard deviation 16%.

Compliance with Mellaril

remained at 100%, standard deviation 0%.

The trend of

the data prior to termination indicated that treatment
with the regimen card aided in appropriate medication
compliance behavior.

Client Four responded positively

to Treatment A using the regimen card and to the
implementation of verbal and graphical feedback in
comparison to baseline measures and the first reversal.
The trend of data, while he participated in the study,
strongly suggests that special packaging and feedback
had a positive effect on improving his compliance. -
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Client Five was undercompliant with the

medication of Prolixin.

Axis x denotes the percentage

of compliance; a x is y designates the number of pill
probe days.
Client Five.

The client was referred to the study

by his Day Treatment Team Leader and pharmacist due to
his reported moderate, short term, undercompliant
behavior with his antipsychot i c medication o f Prolixin
(Figure 9) .

During baseline his mean compliance was

79.8%, with a standard deviation of 37.9%.

Within Weeks

3-4 of .b aseline, he was presented with verbal and
graphical feedback which continued throughout the
remainder of the study.

The initiation of feedback

appeared to have a severe negative effect in that his
compliance behavior dropped to near 0% until the
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introduction of Treatment A, where he achieved a
compliance average of 100 %, standard deviation of 0 %,
for all treatment phases and reversal phases.

In

Treatment A, using the 7-da y baggie special packaging
system, his mean compliance was 10 0% , with a standard
deviation of 0%.

Following a reversal to the vial, he

continu ed to maintain a mean of 10 0 % compliance ,
s tandard deviation of 0 %, and continued t his pattern
throughout al l treatment and reversal phases.

The

c lie nt 's behavior was 100% compliance throughout all
phases of the study except for the last two probes
during base line.

It is difficult to conclude anything

regarding treatment from this subject's be havior.
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Figure 10

Client Six was undercompliant with the

medications of Artane and Loxitane.

Axis x denotes the

percentage of compliance; axis y desigantes the number
of pill probe days.
Client Six.

The client was referred to the study by

his psychiatrist and pharmacist due to his repeat ed l ong
term, severe undercompliant behavior with his
antiparkinson medication of Artane and his antipsychotic
medication of Loxitane (Figure 10) .

Baseline compliance

was at a mean leve l of 90%, standard deviation o f 61%,
for the 4-week period for both medications combined.
For Loxitane his mean compliance level was 63%, standard
deviation 46%.

Baseline mean Artane levels were above

appropriate compliance at 114.5%, standard deviation
69.9%.

These figures were not representative of his

past undercompliant behavior as indicated by his
psychiatrist and pharmacist.

During Weeks 3-4, he was

presented with ve rbal and graphical feedback, which
continued throughout the study.

The introduction of

feedback had a positive effect on his compliance
behavior in comparison to baseline in Weeks 1 and 2.
The mean overall level of compliance during the
treatment phases was 95%, with a standard deviation of
10.6% for both medications.

Loxitane compliance for all

treatment phases was 94%, standard deviation 11%.

His
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mean compliance for Artane in all treatment phases was
95.7%, standard deviation 10.6%.

During Treatment A,

using the 7-day baggie packaging system, mean compliance
was 87% , with a standard deviation of 15%, for both
medications, reflecting little difference between
baseline and the first introduction of treatment.
Individual compliance for Loxitane, however, improved by
24 points to a mean of 87% , standard deviation 16%.
Medication behavior with Artane improved to 87% ,
standard deviation of 16%.

The implementation of

Treatment B, using the regimen card packaging system,
produced an improvement to 100%, standard deviation of
0%, in medication compliance for both Loxitane and
Artane .

The client chose the special packaging

technique of the regimen card for the final weeks of the
study indicated as Treatment C.

His mean compliance was

97.8% , with a standard deviation of 6%, for both
Loxitane and Artane.

Mean compliance with Loxitane

during this phase remained within appropriate levels at
95.7%, standard deviation 8.5%.

Compliance with Artane

remained consistent at 100%, standard deviation 0% .
Overall , the client appeared to benefit slightly by
using the regimen card packaging system as opposed to
the vial and 7-day baggie systems.
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The client achieved a mean of 96%, with a standard
deviation of 7.7%, for all reversal phases for both
medications.

Compliance on Loxitane for all reversal

phases remained at an appropriate mean level of 100%,
standard deviation 0%.

Artane compliance for all

reversal phases also remained at appropriate mean levels
with 92%, standard deviation 9.6%.

Following reversal

to the vial after the introduction of the 7-day baggie
packaging system during Treatment A, his mean compliance
for both medications was 99%, standard deviation of
2.8%.

Loxitane mean compliance at this time improved to

100%, standard deviation 0%, and mean compliance to
Artane improved by 11 points to 98%, standard deviation
4%.

Upon the second reversal to the vial, after using

the regimen card packaging system, his mean compliant
behavior regressed 7 points to 93%, with a standard
dev iat ion of 10%, for bot h medi c ations.

His c ompliance

with Loxitane maintained at 100%, standard deviation 0%,
but Artane compliance deteriorated to 87%, standard
deviation of 10.3%.
Client Six demonstrated a perfect level of
compliance behavior for both of his undercompliant
medications while using the regimen card packaging
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system for Treatment B.

Prior to this phase his

compliance to both regimens varied during baseline.
Upon the implementation of verbal and graphical feedback
his compliance to both medications reached more
appropriate levels of consumption.

The data for this

client suggest that the presentation of feedback helped
to achieve more appropriate consumption of both
medications in his regimen.
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Figure 11

Client Seven was abusive with Artane, and

undercompliant with Navane and Lithium medications.

The

medication of Navane was added to her regimen during
Treatment B, and Lithium during Reversal 2.

Axis x

denotes the percentage of compliance; axis y designates
the number of pill probe days.
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Client Seven.
due to

The client was referred to the study

moderate, long-term, undercompliant and abusive

behavior as reported by her pharmacist and psychiatrist
(Figure 11) .

During the 4 weeks of baseline she

achieved a mean of 94.8%, standard deviation of 14%,
while on Elavil.

This figure was not representative of

her over-and undermedicating behavior as indicated by
both her pharmacist and psychiatrist.

During Weeks 3-4

she was presented with both verbal and graphical
feedback that was continued for the duration of the
study.

The initiation of feedback had a positive effect

on her medication compliance behavior, as exhibited in
the trend of the data beginning in Week 3 of baseline.
Her mean levels of compliance during all treatment
phases with all three medications for the study yielded
98.7% , standard deviation of 12%.

Mean compliance with

Elavil for all treatment phases was within appropriate
levels at 96 .7 %, standard deviation 13%.

Mean

compliance with Navane, which was implemented during
Treatment B, was 100% , standard deviation 0%.

Treatment

A, using the 7-day baggie packaging system , revealed a
mean of 107.5%,with a standard deviation of 15%.
placed on Treatment B, the regimen card packaging

When
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system, the client obtained a mean level of 90%
compliance, with a standard deviation of 22%, for the
medications of Elavil and Navane.

Navane was added to

her regimen at this time by her psychiatrist.
Individual levels of compliance obtained for Elavil
revealed a mean of 87.5%, standard deviation 25%;

mean

compliance with Navane during Treatment B was 100%,
standard deviation 0%.
For reversal phases throughout the study the client
obtained a mean compliance level of 87.8%, with a
standard deviation of 21 .5%, for all three medications
combined.

Mean compliance for Elavil for all reversals

was 83.6%, standard deviation 30 .9%.

Complaint behavior

with Navane also revealed an appropriate mean level at
83%, standard deviation 21% .

Her mean compliance with

Lithium for both reversal phases (reversals Phases 2 and
3) was 87%, standard deviation 18%.

Following reversal

to the vial after the implementation of the 7-day baggie
packaging system during Treatment A, mean compliance was
100%, with a standard deviation of 0%, for Elavil
consumption.

Upon reversal back to the vial following

the regimen card special packaging system, her
medication regimen was altered a second time with the
inclusion of Lithium.

Mean combined compliance with all
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three medications during the second reversal phase
yielded 100.6%, with a standard deviation of 12%.

Her

mean adherence to Elavil was 103%, standard deviation
6%, still remaining within appropriate levels of
compliance.

Mean compliance to Navane during the second

reversal was 98.5%, standard deviation 19.6%, a
regression of 1.5 percentage points.

Mean compliance

with Lithium was 100%, standard deviation 0%.
For the remaining 2 weeks of the study she chose the
vial over the special packaging techniques of the
regimen card and 7-day baggies.

The client's mean level

of compliance for this phase for all three medications
was 63%, with a standard deviation of 33%.
~mplian ce

Mean

to Elavil revealed a mean of 48%, standard

deviation of 28%, a 55-point deterioration in compliance
from the preceding phase of the study.

Adherence to

Navane also regressed 31 points from the preceding phase
to 67 .5%, standard deviation 42.9% .

Her mean compliance

to Lithium was 74%, standard deviation 30.5%, a 26-point
deterioration from the preceding phase.
This client's most appropriate level of medication
compliance was achieved when using the vial, in the
first reversal phase.

However, this trend of

appropriate compliance was set during Treatment A with
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the baggies, suggesting that special packaging had a
positive carry over effect during the first reversal
phase.

Her medication compliance behavior was at it s

worst during the last phase of tre atment.

This

deteri oration in compliance may be attribut able in p a rt
to the confusion caused by the addition of two new
medications to her medical regimen .
In summary, r e sults for Client Seven i ndicated that
she obtained a perfect level of compliance during the
first reversal to the vial.

Baseline measures indicated

an initial fluctuation of both abuse and undercompliance
for her previously defined abusive behavio r o f Elavil.
The implementation of verbal and graphical feedback
produced more appropriate levels of medicat ion
con sumption which was maintained throughout most o f
study with the exception of the third reversa l to t he
v ial.

Dur ing the t hird reversal Navane and Lithi um we re

added to her medical regimen, perhaps making c ompliance
more di f ficult for her.
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Figure 12

Client Eight was abusive with Artane, a nd

undercompliant with Loxitane.

Axis x denotes t he

percentage of compliance; axis y designates the number
of pill probe days.
Client Eight.

The client was referred to the study

by his pharmacist and psychiatrist who reported severe,
long-term abusive and undercompliant behavior with his
antips ychotic medication of Loxitane and his
antiparkinson medication of Artane (Figure 12) .

During

baseline his mean level of compliance was 108%, with a
standard deviation of 23%, for Loxitane and Artane
combined, a figure not representative of the reported
severity of his compliant behavior.

His compliance with

Loxitane during baseline was 100%, standard devi ati on
0%.

Compliance to Artane during baseline exceeded
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appropriate levels , with a mean of 117.6%, standard
deviation 32% .

Within Weeks 3-4, he was presented with

verbal and graphical feedback , which continued
throughout the duration of the study.

The introduction

of feedback had no effect on his compliance behavior.
The Client's overall mean for treatment phases
throughout the study was 132 % compliance , with a
standard deviation of of 47.6%, for the combination of
Loxitane and Artane.

Overall mean for Treatment Phases

A and B was 132%, standard deviation of 47.6%, for both
medications .

Mean compliance for Loxitane for all

treatment phases yielded 96% , standard deviation 23%.
Mean consumption for Artane in all treatment phases was
~yond

appropriate levels_Qf_ compliance with 148 %,

standard deviation 1 . 1 %.

Mean compliance for Treatment

A using the 7-day baggie packaging system, for both
Loxitane and Artane was 114%, standard deviation of
51.6%, an 8-point deterioration in his behavior .

During

Treatment A on Loxitane his mean compliance was at
79 . 5%, standard deviation 39%, a 20.5 point
deterioration in compliant behavior.

Mean compliance to

Artane during Treatment A deteriorated to 149 %, standard
deviation 23% , a 31.4 point change in comparison to
baseline .

Under Treatment B, using the regimen card
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packaging system, mean Loxitane compliance deteriorated
to 112.5%, standard deviation 14%, while mean Artane
compliance improved by 9.5 percentage points to 147.5%,
with a standard deviation of 8.6%.

Mean combined

compliance for both medications during this phase was
130%, standard deviation of 21.7%.
Reversal Phases 1 through 3 produced a comprehensive
mean of 139%, standard deviation of 12.3 0, for both
medications.

Loxitane for both reversals had a mean of

98.9%, standard deviation 1.5%.

Compliance with Artane

for all reversals exceeded appropriate compliance at
184%, standard deviation 25%.

Upon reversal to the vial

following Treatment A using the 7-day baggie packaging
system, adherence to Loxitane improved to 100%, standard
deviation 0%, while compliance to Artane deteriorated
further to 157%, with a standard deviation of 49.7%.
During the second reversal, mean Loxitane compliance
improved to 95.%, standard deviation 8.5%.

Mean

compliance to Artane again exceeded appropriate levels
at 177.5%, standard deviation 26%.

For the final weeks

of the study the client chose to use the vial as opposed
to the special packaging techniques of the regimen card
and the 7-day baggie.

His compliant behavior
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deteriorated to 152.75%, with a standard deviation of
62% , for both medications.

For Loxitane compliance, he

improved to a mean of 100%, standard deviation 0%.

Mean

compliance to Artane was at its worst level during this
phase with a severe degeneration to 202.5%, standard
deviation 39 . 8% .
The client's compliance to Artane deteriorated in
each reversal; where his compliance to Loxitane
deteriorated during each treatment phase, suggesting
that special packaging had a mixed effect on compliance.
Undercompliant Behavior
In review of Group I (those clients who received the
card packaging system first) clients who were
undercompliant in their medical regimens, only one
client, Client 4, was undercompliant with two
medications (Table 3).

This client's level of

medication compliance is described in detail in the
preceding pages under Client 4.
Group II (received the 7-day baggies first)
consisted of 3 clients who were undercompliant in their
medical regimens with a total of six medications (Table
4).

During the 4 weeks of baseline these clients

obtained a mean level of 89%, standard deviation 22.6%,
in compliant behavior.

Beginning at Week 3, verbal and
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graphical feedback was implemented.

It was difficult to

determine the effect of feedback, however, it is
hypothesized due to the trend in data for this group
that there was little effect.

The baseline levels of

compliance was above reported levels of undercompliant
behavior by referring staff.

Upon the initiation of

Treatment A , the 7-day baggie packaging system,
compliant behavior maintained at a mean of 88% , standard
deviation 8.5%.

During the first reversal, mean

compliant behavior improved to 99.5%, standard deviation
1%.

Upon the initiation of the regimen card special

packaging system for Treatment B, mean compliance for
this group reached 100%, standard deviation of 0%.

This

figure was the best level of compliance for the entire
study; following this phase compliance slightly dropped.
During the second reversal to the vial mean compliance
slipped to 96 .7 %, standard deviation 5.5%.

During the

final phase of the study, two of the clients chose the
vial and one client chose the card packaging system to
obtain their medication.

Those clients on the vial

obtained 80.5%, standard deviation of 17%, and the one
client on the card packaging system obtained 97.8% with
a standard deviation of 6%.

Overall reversal phases for
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undercompliant medications in Group II showed a mean of
92%, standard deviation of 10%.

The overall phases mean

compliance for the group was 95%, with a standard
deviation of 6%.
Medication Abusive Behavior
There were three c lients abusing a tota l of four
medications in Group I (Table 3) .

Basel ine measures

revealed a mean of 94% , standard deviation of 8 . 48%, a
figure not representative of the level of abuse reported
by referring parties.

During Week 2, verbal and

graphical feedback was initiated.

The trend of the data

for this group throughout the study suggests that
feedback had l ittle or no effect on clients' selfmedicating behavior.

UEon the initiation of Treatment

A, the regimen card packaging system, compliance
behavior regressed to 125.9%, standard deviation 47 . 1%,
thereby exceeding appropriate levels of compliance.
Reversal to the vial revealed more expected levels of
medication abuse with a mean of 164.1%, standard
deviation of 80%, a difference of 70 points in
comparison to baseline measures.

Upon the initiation of

Treatment B, using the 7-day baggie packaging system,
clients improved in their level of compliance achieving
mean of 123.5%, standard deviation of 29%.

A second
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reversal back to the vial demonstrated another
regression of compliance of 161%, standard deviation
48%.

For the final phase of the study 2 out of the 3

clients chose to remain on the vial, and 1 chose the
special packaging device of the regimen card.

The

results during this phase revealed a mean level of
compliance for those choosing to remain on the vial t o
be 158%, standard deviation of 73%, and 111. 5%, with a
standard deviation of 2%, for the 1 client who chose t he
regimen card for Treatment C.

The overall level of

compliance for the reversal phases was 161 .%, with a
standard deviation of 3%, in comparison to overall
treatment phases of 120% , with a standard deviati on of
7%.

These figures suggest the strong effects of__special

packaging in comparison to the vial in reducing
medication abuse in overmedicating patients.
Abusive behavior for Group II consisted o f 2 clients
overmedicating with a total of three medications (Table
4).

Mean baseline compliance was 105% , standard

deviation .17%, a figure that was not representative of
the actual level of abuse reported by referring
agencies.

Implementation of Treatment A, the 7-day

baggie packaging system, brought about a deter i orat i on
of appropriate medication consumption to 12 7 .5%,

83
standard deviation 30%.

Reversal to the vial yielded

compliance of 128.5%, standard deviation of 40%.

The

implementation of the regimen card special packaging
system for Treatment B improved the medication
compliance mean to 117.5%, standard deviation 42%.

Upon

reversal to the vial , compliance deteriorated again to a
mean of 140%, standard devi ation 52%.

For the final

phase of the study, both clients preferred to remain on
the vial as opposed to the special packaging systems
offered.

Mean compliance again exceeded the appropriate

levels of consumption at 11 6 . 8% , standard deviation
78. 6% .

Overall levels of compliance during the reversa l

phases for this group yielded 128% , standard deviation
11 .6%, in compliant behavior.
compliance

du~ing

Overall level of

treatment phases was 122.5%, standard

deviation 7%, a 6- point improvement in compliant
behavior.

These results suggest that the implementation

of the special packaging produced more appropriate
levels of medication compliance in comparison to
reversal Phases 1 and 2, but not baseline.

The best

level of compliance occurred during baseline and
Treatment B with the implementation of the regimen card .
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Table 3
Undercompliant and Abusive Data For Group I

Undercompliant Medication Only On Group I:

Receivin~

Cards First

~

Condition

M Cin percenta&es)

SIL

Overall M & SD

1-3

Baseline

68.4%

24.8%

For Reversals 1&2
M = none, SD = none

4-6

Treatment A

100.0%

0.%

For Treatment Phase A

M =100%,Sll =0%

7-8

Reversal 1

95.%

7.07%

9-10

TreatmentB

none

none

11-12

Reversal 2

none

none

13-14

Treatment C/

none

none

(Reversal 3)

N=1 (Client 4))
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Abusive Medication Only On Group 1:

Recejyin~

Cards First

Week

Condition

M Cin percentages)

SlL_

Overall M & SD

1-3

Baseline

94.%

8.48%

For Reversals 1&2

M=
4-6

Treatment A

47.1%

125.9%

161.%, Sl2 = 3%

For Treatment Phases

M =120%,SD= 7%

7-8

Reversal!

164.1%

80.%

9-10

Treatment B

123.5%

29.%

11-12

Reversal 2

161.%

48.%

13-14

Treatment C

111.5%

50.%

158.%

73.%

N=3 (Clients 1, 2, 3)

(cards) or

13-14

Reversal 3

Table4
Undercompliant and Abusive Data For Group II

Undercompliant Medication Only In Group II: Receiving Baggies First
Week

Condition

M Cin percentages)

1-4

Baseline

89.%

22.6%

.sJ2.

Overall M & SD
For Reversals
M = 92%, SD = 10%
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5-7

Treatment A

88.%

For Treatment

85.%

M = 96.0%, S12 = 6.3 %

8-10

Reversal 1

99.5%

1.%

11-13

Treatment B

100.%

0.%

14-16

Reversal 2

96.7%

5.5%

17-19

Treatment C

97.8

6.%

80.5%

17.%

N=4 (Clients 5, 6, 7, 8)

(cards) or
17-19

Reversal 3

Abusive Medication Only In Group II: Receiving Baggies First
Week

Condition

M (in percentages)

1-4

Baseline

105.%

17.%

SD

Overall M & SD
For Reversals
M = 128%, SD 11.6%

4-7

Treatment A

127.5%

30.%

For Treatment ·
M

8-10

Reversal 1

128.5%

40.%

= 122.5%,

.s..Q =7%
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11-13

Treaunent B

117.5%

42.%

14-16

Reversal 2

140.%

52.%

17-19

Reversal 3

116.8

78.6%

N=2 (Clients 7, 8)

Discussion
The results obtained in the present study support
the previous findings of Demetral et al. (1978) that the
use of special packaging in comparison to baseline
measures and reversals with the vial enhances medication
compliance among noncompliant psychiatric outpatients.
Medication Abuse
Abusive clients within Group I

(who received the

regimen card system for the first treatment phase)
demonstrated more appropriate levels of compliance while
using the special packaging techniques in comparison to
reversals while using the vial.

Treatment B, while

using the 7-day baggie packaging system, yielded
slightly better results than that of the regimen card
packaging system by 2.4 percentage points.

Starting

with the regimen cards for Treatment A may have had an
influence in setting the appropriate trend in compliance
for the baggies.

Dramatic differences were found

between Treatment A and B Phases in comparison to
reversal Phases 1, 2, and 3.
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Abusive clients within Group II demonstrated more
appropriate levels of compliance during Treatment B,
while using the regimen card special packaging system,
in comparison to Treatment A, using the 7 -day baggie
system, and in reversal Phases 1, 2, and 3.
Undercompliance
Within Group I

(those who received the card system

first), there was 1 client who demonstrated appropriate
compliance behavior following the initiation of the
regimen card special packaging technique.

Upon the

initiation of the first reversal to the vial there was a
slight regression in compliance.

It is hypothesized

that the level of compliance obtained during the first
treatment phase would have continued throughout the
study if the client had continued to participate in the
program .
Undercompliant clients in Group II (who received the
baggie system first)

demonstrated a trend which s u ggests

the implementation of the regimen card special packaging
system, during Treatment B, to produced the best level
of compliance compared to baseline, reversal phases, and
Treatment A using the 7-day baggies .

Within the final

phase of the study 1 client chose to continue using the
regimen card package, while the remaining 3 clients
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chose the vial.

Medication compliance during this phase

was within appropriate levels of consumption, but it did
not yield the perfect compliance obtained while these
clients were using the regimen card packaging system .
Benefits of Special Packaging
As hypothesized, medication compliance with the
regimen card packaging system yield the best compliance
levels for undercompliant clients, most likely due to
the provision of visual feedback to the clients .

Many

undercompliant clients are forgetful as to the time they
are to consume their medications and the number of pills
to be taken.

With the implementation of the regimen

card, these clients were able to detect easily when they
were to consume their medications; the card also
provided them with information regarding how many pills
they had or had not taken.

The more appropriate level s

of consumption obtained with abusive clients when using
the regimen card may also be attributed to the card's
visual feedback feature .

The information the card

provided as to the number of pills they had taken during
a particular day, as well as over a week's period, may
have limited clients' level of abuse through providing
concrete information as to their degree of medication
abuse .
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Overall, the results indicated that regardless of
which special packaging system was introduced first as
Treatment A, the regimen card packaging system yielded
the most appropriate levels of medication compliance for
those clients who benefitted from the special packaging
techniques.

Differences were found between the effects

of the two special packges depending on which system the
clients were started on .

In review of Groups I and II

when the sequencing of treatment phases was the cards
followed by the baggies as in Group I, mean compliance
levels for overmedicators was 125.9% in comparison to
those in Group II who received the baggies first
obtaining a mean 127.5% compliance.

Undercompliers in

Group I obtained a mean of 100% compliance when
beginning on the card and 88% for Group II receiving the
baggies first.

This indicates that the use of regimen

card, when introduced during the first phase of
treatment, yields better compliance in comparison to
starting with the baggies.

Perhaps it was easier to see

the separate doses to be taken when using the card, and
that this helped to set a trend for more appropriate
levels when using the baggies.
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Casual observations suggest that most clients who
abuse their medication were unaware as to the degree
they were overmedicating.

Three abusive clients

(Clients 2, 3, and 8) revealed that their mode of
consuming medications, prior to the implementation of
the study, was to hold up a medication vial to their
mouth and then taking a swallow as if the v i al were a
glass containing liquid.

One abusive client (Client 2)

confessed that during the times he ran out of Artane
(during the first 2 days of the week), he would make
street purchases for more than $1.00 per pill to relieve
his Parkinsonian-like symptomatology .

(Apparently the

overmedicating during the beginning of the week was to
achieve a 'high' for a couple of days.)

Two

undercompliant clients (Clients 6 and 7) and one
overcompliant client (Client 3) revealed to me that due
to the number of different pills in their weekly regimen
they had felt confused, and at times it was very
difficult to get the prescription instructions straigh t.
Implementation of the

special packaging techniques

presented clients with hard to ignore, yet easy to see
evidence of the seriousness of their overmedicating
behavior.

Two clients preferred the visual aid

advantage of the regimen card system over the vial and
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requested to be a part of the Community Re-entery
Projects program in order to continue use with this
packaging device.
However, more clients preferred the vial, as opposed
to the special packaging of their medications, when
given the choice.

Questioning revealed that some

abusive clients (Clients 1,2, and 8) did not like
knowing the degree of their abusive behavior.

They were

generally unaware of the amount of medication they were
ingesting at the beginning of a week until using the
special packaging techniques.
The degree of noncompliance exhibited by the clients
in this study took their psychiatrists by surprise.
Most of them were completely unaware of the degree of
over-and undermedicating in which clients were engaging.
The majority of these psychiatrists conveyed to me their
plans to change the regimen of their clients' medication
and/or place them on 1-day-medication-compliance
following the termination of the study or during its
final phase.

Two psychiatrists inquired of their

clients' best level of compliance during the study.
Upon learning that the best levels obtained were when
clients were using special packaging techniques, they
further inquired how they might be able to maintain
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their clients on one of the packaging systems following
termination of the study.
Problems Associated With the Study
Referring agencies indicated that the clients in
this study were much more noncompliant than the initial
baseline revealed the clients to be.

While complinance

during reversals seemed to be more congruent with the
referrals.

This is strong evidence for reactivity in

the initial baseline.

By the time of the first reversal

within the study , clients may have felt more comfortable
with the study and the pill counts, and thereby fell
back into more "natural" levels of consumption of
medications, as opposed to during baseline.

Longer

baseline and treatment phases should have been
implemented in order to alleviate this problem.
Verbal and graphical feedback had little effect on
compliance, and its contribution to the study was
difficult to determine.

Longer phases with verbal and

graphical feedback implemented without the inclusion of
packaging could have been used in order to note the
benefits of this variable in the study.

94
Future Research Interventions
Recommendations for future research include changes
in the regimen card, longer intervals for treatment
phases, and longer phases of baseline.
Some modifications of the regimen card packaging
system could enhance compliance.

The card might be

designed to fit into the back pocket, coat pocket, or
purse of a client to enable them to carry the packaging
system with them wherever they go.

This would be more

convenient than folding it in half, or bending the
system in such a way as to cover the prescription
instructions , which was noted during the present study.
Investigating special packaging effects with those
who abuse their medications provides more reliab l e pill
count data than with those who undermedicate, since a
pill taken is a pill missing .

Overmedicators might be

tempted to take to the streets to purchase additional
pills; however, it would be difficult to time the
consumption of street versus card pills in such a way as
to simulate appropriate compliance.

For instance, the

client would have to purchase a large number of pills on
the street for a price, hide them, and dip into this or
her stash throughout the week or engage in daily buying
of pills so as not to disrupt the special unit dose
packaged medications held within the regimen card.
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Further, most clients do not have enough funds to
purchase large amounts of additional medications and
rarely can spare the price and bother of buying
additional daily pills.
The regimen card packaging system has many
advantages over the standard medication vial and the 7day baggies.

Its design further aids clients in

complying as directed and provides them with immediate
feedback as to their level of compliance on a given day.
The vial provides no feedback as to the number of pills
taken or not taken without emptying the entire contents
of the vial and counting each pill.

This technique to

check compliance is very tedious, especially if clients
need to check whether or not they have taken their pill
several times a day, and with several medications in
their regimen.

The regimen card's visual display of

pills was also found to be more helpful to clients in
comparison to the baggie package.

Clients were able to

open their card for a particular day and immediately
note their level of compliance.

Using the baggies,

clients needed to empty the contents of their bag for a
particular day, and then review each additional bag
inside labeled for the time frames of consumption, and
check their compliance.
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Thus the implementation of special packaging using
the regimen card system has significant benefits.

The

present study has demonstrated the regimen card's
advantages in yielding more appropriate compliance
levels among both under-and overmedicators.

The

implementation of this packaging system has particular
importance with abusive medication compliers in helping
physicians give additional help in the f orm of visual
feedback to their outpatients in proper self-medication
behavior, thereby decreasing recidivism and
rehospitalization rates.

In addition, the regimen card

can help in reducing the number of visits abusive
clients make to their pharmacist in which to obtain more
medication on daily or weekly bases, and cut down on the
frequency of purchasing additional medications on the
street for a price.

Overall, the regimen card has

significant beneficial effects for the abusive client
and would be worth further investigation of its
effectiveness with other drug abusing populations.
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Appendix A
Participant Recruitment Letter
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Dear

-------------------My name is Nicole Miller.

I am a graduate student

at the University of the Pacific, working on my master's
degree in Applied Behavior Analysis Psychology.
At present I am working on my thesis project.

I am

studying the effects of special packaging techniques on
medication compliance with chronic outpatients
affiliated with the mental health system.

My hypothesis

is that, with the aid of special packaging techniques,
compliance behavior will increase.
I am writing to you in hopes that you can aid me in
obtaining outpatients for this research.

I am looking

for outpatients who are suspected of having problems
with complying to their medication regimen(s).

Failure

in compliance, for the purpose of the present study,
consists of a patient who has failed to comply with his
or her prescribed daily regimen of medication by
consuming too little or too much of his or her
medication regimen(s) during the time frames designat ed
by his or her prescribing physician.

The present study

will begin in April and terminate in August.

105
I would appreciate your assistance in referring
clients who fit the above description and who you feel
would most benefit from such a program.

I will be

calling you in the near future to arrange a time in
which we can meet to demonstrate the special packaging
techniques that will be used, and to further explain the
present study in more detail.
With sincere thanks,
Nicole Miller

eel
RS
BH
JB

KT
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Appendix B
Referral card/consent form

107

Medication Cornoliance Program
Client lnforrnatlOD form
Client Name:

!de d . Como . Coo rainat o r Info .

Address:

Assigned Staff :

Phone No.:

Client Accept Date :

Initial Meeting Date :

Client Te rminate Date :

Referral Source:

Reason for Termination:

Doctor(s) :
Client Availability: Days : ___________
Ti me :

-----------

Alternative Sources o:t Contact:

Client Diagnosis:

Other Info.

Staf! Signature and Date :

Date :

I
I

I
I
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Appendix C
Request for doctor's assistance form

~ ---
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Dear Dr.

-------------------

Thank you for referring clients to the Medication
Compliance study.

I have obtained a random list of

clients for my research.

One of your clients,

several of your clients),
chosen to participate.

(or

, has/have been

Each client's medication will be

filled at the Mental Health Center's pharmacy and
packaged in the special packaging systems of the regimen
card and the 7-day baggie

system by the University of

the Pacific's pharmacy intern.
The packaging systems mentioned above involve
packaging 7 days of medication into unit dose plastic
containers.

The medications divided into 7 daily bags

or cards, and medication regimens are separated by the
time of day.

This system is designed to provide the

client with direct feedback concerning the type of
medication and time of day it is to be taken, thereby
alleviating the problems with under-and overmedicators.
If you have any questions or concerns , please do not
hesitate to contact me.

110
In order for-------------to participate in the
Medication Compliance study, I need you to read and sign
the statement written below, and return it to me.
Thank you.
Sincerely,
Nicole Miller

I give my permission for

-------------------to

participate in the Medication Compliance study, and to
have his or her medication(s) packaged in the special
techniques of the regimen card and 7-day baggie, at the

I

Mental Health Center's pharmacy, and package d by the
University of the Pacific's pharmacy intern.

f

X

---------------------------

I

I_

I
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Appendix D
Consent for participation
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1.

I give my physician permission to call the

medications prescribed for my use to the San Joaquin
Mental Health Center's pharmacy.

I a lso give San

Joaquin Mental Health Center's pharmacy and their staff
permission to package the medications in the special
packaging systems of the regimen card, the 7-day baggie,
and in the medication vial, which have been exp l ained to
me .

The expe rimenter will then return the medication to

me at the previously arranged dates and times.

2.

In add ition , I agree to let the exper ime nter

have access to my outpatient personal fi le in which to
aid her in my medicatio n treatment.

3.

I also agree to part i cipate in the medication

packaging program for the duration of the study, a
de signated time frame of 4 months (April through July),
and to comply with the experimenter to the bes t of my
ability .

4.

I understand that the medications from seve r al

prescriptions will b e packaged together with each
individual dose packaged in a presealed container .

I

113

also understand that the system is not child resistant
and to keep it out of children's reach at all times.
The above procedure has been thoroughly explained to me
and any questions I may have concerning this procedure
have been answered to my complete satisfaction.

Experimenter's

Client's

Signature: --------------- Date: -----------

Signature:

-------------------- Date: -----------

Client's Address & Phone No.:

Best times to be reached:

-----------------------------

----------------------------------
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Appendix E
Individual Data For Groups 1 and 2
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Individual Data For Group I

Client One: Individual Raw Data (Group D
Condition

Medication(s) M (in percentage) .s.IL

Overall M & SD

Baseline

Artane

For Reversals

M= 104.4%

16.4%

M..= 138%, Sl2 = 33.0%

Treatment A Artane

M= 121.8%

13.3% For Treatments A&B
M =124.9%, SD=4%

Reversal 1 Artane

M= 168.0%

36.8%

Treatment B Artane

M= 128%

16.2

Artane M = 119%,
SD = 16.5%

Reversal 2 Artane

M= 142.4%

42.5%

Elavil M = 99.8%,
.s..Q= 13

Reversal 3 Combined

M= 103.0%

14.47%

Artane

M= 106.0%

14.5%

Elavil

M= 99.8%

13.5%

.
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Client Two: Individual Raw Data CGroup J)
Baseline

Artane

M= 173.0%

85.%

For Reversal M= 148.5%,
S.I2=75

Treatment A Artane

M= 193.5%

45.6%

Artane M = 230.5%,
S.I2=34%

Reversal 1

Artane

M= 270.0%

2.4%

Tofranil M= 133%,
S.I2=0

Treatment B Artane

M= 163.0%

31.2

Cogentin M = 82%,
SD = 35%

Reversa13

Combined

M= 141.6%

59.76% For Treatment A&B- M=178 %,SD=21.5%

Artane

M= 210.0%,

SD=O%

Tofranil

M = 133.0%,

SD=O%

Cog entin

M= 82.0% '

SD=35%

Client Three: Individual Raw Data (Group D
Baseline

Artane

M= 115.0%

29. %

ForReversals M = 109%,
SD=46.9 %

.

Treattnent A Combined

M= 95.0%

12.8%

Artane

M = 164%,

SD = 58.9%

Reversal !

Artane

M= 100.0%

0 .%

Lithium

M = 97.%,

Lithium

M= 88.6%

19.6%

SD = 21 %

Combined

M= 109.0%

46.9%

For Treatments ABC
M =103 %,SD=12%

Artane

M= 141.0%

37.%
Artane M = 104.8%,
SD = 10%

Lithium

M= 76.75%

31.%
Lithium M = 96.7%,
SD = 21%

Treatment B Combined

l

I
I

Reversal2

M= 101.5%

2.8 %

Artane

M= 101%

2.5%

Lithium

M= 101.7%

3.5%

Combined

M= 145%

72.%

Artane

M= 187.5%

72.%

Lithium

M= 102.75%

46.6%

M= 113%

15.6%

M= 110%

12.92%

Treatment C Artane
Lithium

Client Four: Individual Raw Data In Group I
Baseline

Combined

M= 68.58%

39.6%

Lithium

M= 50.8%

44.5 %

Mellaril

M= 86.0%

26.8%
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M= 100%

0.%

Lithium

M= 100%

0.%

Mellaril

M= 100%

0.%

Combined

M= 95.0%

11.8%

Lithium

M= 90.0%

16.%

Mellaril

M= 100%

0.%

Treatment A Combined

Reversal 1

Treatment B (Terminated from study)

Reversa12

(Terminated from study)

Individual Data For Group II

Client Five: Individual Raw Data In Group TI
Condition

Medication(s) M Cin percenta~es) .s.IL

Baseline

Prolixin

79.8%

37.9%

Qverall M &SD
For Reversals M = 100%,

Sl2=0%

Treannent A Prolixin

100.%

0.%

For Treattnent A&B

M =100%,Sl2 =0%

.

Reversal 1

Prolix.in

100.%

0.%

Treaunent B Prolix.in

100.%

0.%

Reversal 2

Prolixin

100.%

0.%

Reversal 3

Prolixin

100%

0.%

1 19

Client Six: Individual Raw Data In Group II
Baseline

Combined

90.%

61.%

For Reversals M = 96%,
SD =7.7%

Lox.itane

63.%

46.%

Loxitane M= 100%,
SD=O%

Artane

114.5%

69.9%

Artane M=92%,
SD=9.6%

Treaunent A Combined

87.%

15.%

-

For Treaunents ABC
M=95%,S12=10.6%

Lox.itane

87.%

16.%

Loxitane M=94%,
SD = 1%1

Artane

87.%

16.%

Artane=M=95.7%,
SD=10.6%

Reversal 1

Combined

99.%

0.%

Lox.itane

100.%

0.%

Artane

98.%

4.%

.

Treatment B Combined

100.%

0 .%

Loxitane

100.%

0.%

Artane

100.%

0.%

93.%

9 .10%

Loxitane

100.%

0.%

Artane

86.%

10.3%

97.8%

6.

Loxitane

94.%

11.

Artane

100%

0 .%

Reversal 2

Combined

Treatment C Combined
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Client Seven Individual Raw Data In Group II
Baseline

Elavil

94.8%

14.%

For Reversals 87 .8%,

.su = 21.5%
Treatment A Elavil

107.5%

15.%

Elavil M= 83.6%,

SJ2 = 30.9%
Reversal 1

Elavil

100%

0.%

Navane M
SJ2=21%

= 83%,
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Treatment B Combined

90.%

22.3%

Lithium M= 87%,
SJ2=30.5%

Elavil

87.5%

25.%

For TreatmentsA&B
M=98.7%,SJ2=12%

Navane

100.%

0 .%

Elavil M =96.7%,
SJ2=13

Reversal 2

Combined

100.6%

0.%

Navane M = 100%,

.s.u = 0

Reversal 3

Elavil

103.%

6.%

Navane

67.5 %

42.9%

Lithium

100.%

0.%

Combined

63.%

33.%

Elavil

48.%

28.%

Navane

67.5%

42.9%

Lithium

74.%

30.5%

Client Ei eht: Individual Raw Data In Group II
Condition

Medication(s) M (in percentages) SD

Overall M & SD

Baseline

Combined

For Reversals M =139%,

108.%

23. %

SD= 12.30%
Loxitane

100.%

0.%

Loxitane

M =98.9%,

SJ2 =1.5%
Artane

117.6%

23.%

ArtaneM= 184%,
SD = 25%
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Treatment A Combined

114.%

51.6%

For TreatmentsA&B
M=132%,.s.Q=47%

Loxitane

79.5%

39.%

M =96%,

Loxitane
SQ=23%

Artane

149.%

23.%

Artane M = 148%,
SQ=l.l%

Reversal!

Reversal2

I

Combined

128.6%

44.%

Loxitane

100.%

0.%

Artane

157.%

49.7%

Combined

136.6%

47.%

Loxitane

95.8%

8.5%

Artane

177.%

26.%
-

Treatment B Combined

Reversal 3

130.%

21.7%

Loxitane

112.5%

14.%

Artane

147.5%

8.6%

152.75%

62.%

Loxitane

100.%

0.%

Artane

202.5%

39.8%

Combined

-

----

